Genelux Corporation (GNLX)
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Our most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity.
We expect to be in the process of obtaining Institutional Review Board approvals and negotiating clinical trial agreements to begin enrollment for our Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer in the second quarter of 2022.
Employing our proprietary selection technology and discovery and development platform (CHOICE), we have developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.
These provide potential utility in multiple tumor types in both the monotherapy and combination therapy settings, via physician-preferred administration techniques, including regional (e.g., intraperitoneal) and systemic (e.g., intravenous) delivery routes.
Informed by our CHOICE platform and supported by extensive clinical and preclinical data, we believe we have the capacity to develop a pipeline of treatment options to address high unmet medical needs for those patients with insignificant or unsatisfactory responses to standard-of-care therapies, including chemotherapies.
From this library, we selected Olvi-Vec, which we believe has the potential to exhibit anti-tumor properties, including potent oncolytic properties (tumor cell lysis) and to activate both the innate and adaptive arms of the immune system, to produce favorable changes within the tumor microenvironment.
The personalized and multi-modal immune activation generated by Olvi-Vec is designed with the goal to yield clinically-meaningful anti-tumor responses to virus treatment alone and in combination with other existing treatment modalities.
|CEO||Thomas Zindrick, J.D.|
2625 Townsgate Road, Suite 230
Westlake Village, CA 91361
|Thomas Zindrick, J.D.||President, Chief Executive Officer and Chairman|
|Paul Scigalla, M.D., Ph.D.||Chief Medical Officer|
|Tony Yu, Ph.D.||Vice President, Clinical Trial Operations|
|Joseph Cappello, Ph.D.||Vice President, Pharmaceutical Development and General Manager of Manufacturing|
|Qian Zhang||Associate Vice President, Research|
|Sean Ryder||General Counsel and Corporate Secretary|
|John Thomas, Ph.D.||Director|
|James L. Tyree||Lead Independent Director|
Latest SEC Filings
|Nov 4, 2022||FWP||Free Writing Prospectus|
|Nov 4, 2022||S-1/A||[Amend] General form for registration of securities under the Securities Act of 1933|
|Oct 13, 2022||S-1/A||[Amend] General form for registration of securities under the Securities Act of 1933|
|Oct 4, 2022||FWP||Free Writing Prospectus|
|Sep 19, 2022||S-1/A||[Amend] General form for registration of securities under the Securities Act of 1933|
|Aug 29, 2022||S-1/A||[Amend] General form for registration of securities under the Securities Act of 1933|
|Jun 24, 2022||S-1||General form for registration of securities under the Securities Act of 1933|
|May 20, 2022||DRS/A||[Amend] [Cover] Draft Registration Statement|
|Jun 24, 2021||DRS/A||[Amend] [Cover] Draft Registration Statement|
|May 7, 2021||DRS||[Cover] Draft Registration Statement|